The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Bromocriptine results in increased expression of ABCB1 protein Clozapine inhibits the reaction [Bromocriptine results in increased expression of ABCB1 protein]; Spiperone inhibits the reaction [Bromocriptine results in increased expression of ABCB1 protein]
Bromocriptine results in increased activity of ABCB1B promoter Bromocriptine results in increased expression of ABCB1B mRNA Clozapine inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; eticlopride inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; Pertussis Toxin inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; Spiperone inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]
Bromocriptine results in increased expression of AKR1C3 mRNA methyl cellosolve inhibits the reaction [Bromocriptine results in increased expression of AKR1C3 mRNA]
Bromocriptine inhibits the reaction [methyl cellosolve results in increased expression of CYP11A1 mRNA] Bromocriptine results in decreased expression of CYP11A1 protein
Bromocriptine binds to CYP3A4 protein CYP3A4 protein affects the metabolism of Bromocriptine Bromocriptine inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]
Bromocriptine affects the expression of DRD2 mRNA DRD2 protein affects the susceptibility to Bromocriptine Bromocriptine binds to and results in increased activity of DRD2 mRNA; Bromocriptine promotes the reaction [Clozapine results in decreased expression of DRD2 mRNA] Bromocriptine results in decreased expression of DRD2 mRNA [Clozapine co-treated with Bromocriptine] results in decreased expression of DRD2 mRNA Bromocriptine results in increased expression of DRD2 mRNA DRD2 polymorphism results in increased susceptibility to Bromocriptine
[1-Methyl-4-phenylpyridinium co-treated with Bromocriptine] results in decreased expression of DRD3 mRNA Bromocriptine results in decreased expression of DRD3 mRNA
[Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Bromocriptine binds to and results in decreased activity of HTR7 protein
[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of PCNA protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PCNA protein]
Bromocriptine results in decreased expression of POMC protein alternative form Bromocriptine results in increased expression of POMC mRNA; Bromocriptine results in increased expression of POMC protein modified form Bromocriptine inhibits the reaction [POMC protein results in decreased secretion of Corticosterone]
Bromocriptine promotes the reaction [Estrogens results in increased expression of and results in increased cleavage of PRKCD protein] Bromocriptine affects the localization of PRKCD protein
Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Nalorphine results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [VIP protein results in increased expression of PRL protein] Bromocriptine results in decreased secretion of PRL protein Bromocriptine results in decreased expression of PRL protein Bromocriptine inhibits the reaction [Amisulpride results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PRL mRNA]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Estradiol results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [methyl cellosolve results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [Olanzapine results in increased expression of PRL protein]; Estradiol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Ethanol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Sulpiride inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]
Bromocriptine inhibits the reaction [[SOD1 protein mutant form co-treated with Lipopolysaccharides] results in increased secretion of TNF protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of NOS2 protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of TNF protein]
[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of TGFB1 protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in decreased expression of TGFB1 protein]
Bromocriptine inhibits the reaction [[SOD1 protein mutant form co-treated with Lipopolysaccharides] results in increased secretion of TNF protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of TNF protein] Bromocriptine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of VEGFA protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in decreased expression of VEGFA protein]
Bromocriptine inhibits the reaction [VIP protein results in increased expression of PRL protein] [Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of VIP protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of VIP mRNA]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of VIP protein]